- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07942402
Impact of Preoperative Urine Culture Following Transurethral Resection of the Prostate (UROCULTURP). (UROCULTURP)
Impact of Preoperative Urine Culture on the Prevention of Postoperative Urinary Tract Infections Following Transurethral Resection of the Prostate in Men With Benign Prostatic Hyperplasia: Protocol for a Multicenter, Parallel-group, Randomized Non-inferiority Diagnostic Test Trial.
Benign prostatic hyperplasia (BPH) is a common condition in men, and a proportion of affected patients require surgical treatment. Transurethral resection of the prostate (TURP) is considered the gold standard for the surgical management of these patients. Preoperative asymptomatic bacteriuria (ASB) is present in approximately 30% of patients with BPH undergoing TURP. Current guidelines recommend screening for and treating ASB before endoscopic urological procedures associated with mucosal trauma to prevent postoperative infectious complications. However, the precise role of ASB in the development of postoperative urinary tract infections (UTIs) remains unclear, and the quality of the evidence supporting these recommendations is low.
A prospective, comparative clinical study is therefore warranted to determine the effectiveness of preoperative screening for and treatment of ASB in preventing infectious complications in patients with BPH undergoing TURP. The findings may help address existing knowledge gaps, inform future recommendations, and promote adherence to evidence-based clinical decision-making.
The objective of this study is to determine the effectiveness of preoperative screening for and treatment of ASB in preventing postoperative infectious complications in patients with BPH undergoing TURP.
A multicenter, parallel-group, randomized non-inferiority diagnostic test trial is proposed. A total of 1,262 men aged over 45 years with a diagnosis of BPH, an indication for TURP due to BPH, and no signs or symptoms of UTI will be enrolled. Participants will be randomly assigned in a 1:1 ratio to one of two groups according to whether the results of the preoperative urine culture are disclosed or withheld. Participants will be followed up for one month, and the primary outcome will be the occurrence of urinary tract infection (UTI).
The study was approved for review by the Research Ethics Committee of the Faculty of Medicine at the University of Antioquia and by the ethics committees of all participating institutions involved in patient recruitment.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Francisco L Caro, MD, Urologist
- Número de telefone: +57 604-219-8332
- E-mail: francisco.caro@udea.edu.co
Estude backup de contato
- Nome: Ivan D Florez, MD, MSc, PhD
- Número de telefone: +57 313 7421132
- E-mail: ivan.florez@udea.edu.co
Locais de estudo
-
-
Antioquia
-
Medellín, Antioquia, Colômbia
- Hospital Alma Mater de Antioquia
-
Contato:
- Deimer E Mercado, MD, Urologist
- Número de telefone: +57 604-219-6940
- E-mail: deimer.mercado@udea.edu.co
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Men aged >45 years with a diagnosis of benign prostatic hyperplasia (BPH).
- Indication for transurethral resection of the prostate (TURP) for BPH.
- Absence of signs or symptoms of urinary tract infection (UTI).
Exclusion Criteria:
- Symptomatic urinary tract infection (UTI) or antibiotic treatment within the previous month for a UTI or any other infectious condition.
- Patients scheduled to undergo additional transurethral procedures during the same surgical session (e.g., urethrotomy, transurethral resection of a bladder tumor [TURBT], or cystolithotomy).
- Diagnosis of prostate cancer.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Disclosure Group
Disclosure of preoperative urine culture results |
In this arm, the results of the preoperative urine culture will be made available to the treating urologist. |
|
Outro: Non-Disclosure Group
Non-disclosure of preoperative urine culture results |
In this arm, the results of the preoperative urine culture will not be made available to the treating urologist. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Urinary tract infection (UTI)
Prazo: 30 days or 1 month
|
UTI was defined according to the American Urological Association (AUA) antimicrobial prophylaxis guidelines (43), supplemented by the European Association of Urology (EAU) UTI diagnostic criteria (10). Patients were classified as having a UTI if they met any of 4 scenarios: (1) ≥1 urinary symptom or fever, positive urine culture (>10⁵ CFU), and surgeon-confirmed post-endoscopic UTI; (2) ≥2 urinary symptoms or fever plus supportive laboratory findings or clinical diagnosis; (3) postoperative fever with imaging suggestive of pyelonephritis after TURP, or catheter-associated UTI with ≥10³ CFU/mL within the specified catheterization period; or (4) ≥2 persistent urinary symptoms for >1 week after catheter removal, without fever or improvement, plus positive urine culture (>10⁵ CFU) and surgeon-confirmed post-endoscopic UTI. |
30 days or 1 month
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Urinary sepsis
Prazo: 30 days or 1 month
|
Patients will be diagnosed with rrinary sepsis if they meet the criteria:
In clinical practice, organ dysfunction may be indicated by a Quick Sequential Organ Failure Assessment (qSOFA) score of ≥2. The qSOFA criteria are a respiratory rate of ≥22 breaths/min, altered mental status, or systolic blood pressure of ≤100mmHg. Septic shock will be defined as the requirement for vasopressors to maintain a mean arterial pressure of ≥65 mmHg, together with a serum lactate level of >2 mmol/L(>18 mg/dL), in the absence of hypovolemia |
30 days or 1 month
|
|
Acute orchiepididymitis
Prazo: 30 days or 1 month
|
Acute orchiepididymitis will be defined as the presence of scrotal pain, swelling, increased temperature, and inflammatory changes, accompanied by testicular and/or epididymal tenderness and enlargement on palpation; or inflammatory changes involving the testis and/or epididymis, with increased blood flow on color Doppler ultrasonography, with or without intratesticular collections on ultrasound examination. These findings may occur regardless of whether the urine culture is positive. |
30 days or 1 month
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Francisco L Caro, MD, Urologist, Universidad de Antioquia
- Diretor de estudo: Ivan D Florez, MD, MSc, PhD, Universidad de Antioquia
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SIIU2024-78410
- IN70-2024 (Outro identificador: Hospital Alma Mater de Antioquia)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .